非霍奇金淋巴瘤患者血浆 miR-92a 水平下调的临床影响。

Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.

机构信息

Hematology Division, First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.

出版信息

PLoS One. 2011 Feb 24;6(2):e16408. doi: 10.1371/journal.pone.0016408.

BACKGROUND

We undertook a study to evaluate the clinical relevance of miR-92a in plasma obtained from non-Hodgkin's lymphoma (NHL) patients, because the miR-17-92 polycistronic miRNA cluster plays a crucial role in lymphomagenesis and affects neo-angiogenesis.

METHODOLOGY/PRINCIPAL FINDINGS: Plasma miR-92a values in NHL were extremely low (<5%), compared with healthy subjects (P<.0001), irrespective of lymphoma sub-type. The very low plasma level of miR-92a increased in the complete response (CR) phase but did not reach the normal range, and the plasma level was lower again in the relapse phase. Patients in CR or CR unconfirmed with a plasma miR-92a level of less than the cut-off level showed a significantly high relapse rate compared with patients with normalized plasma miR-92a level.

CONCLUSIONS/SIGNIFICANCE: The current results therefore indicate that the plasma miR-92a value could be a novel biomarker not only for diagnosis but also for monitoring lymphoma patients after chemotherapy.

背景

我们进行了一项研究，评估非霍奇金淋巴瘤（NHL）患者血浆中 miR-92a 的临床相关性，因为 miR-17-92 多顺反子 miRNA 簇在淋巴瘤发生和影响新血管生成中起着至关重要的作用。

方法/主要发现：与健康受试者相比（P<.0001），NHL 患者的血浆 miR-92a 值极低（<5%），与淋巴瘤亚型无关。完全缓解（CR）期的 miR-92a 血浆水平升高，但未达到正常范围，缓解期再次降低。miR-92a 血浆水平低于临界值的 CR 或未确认 CR 的患者与 miR-92a 血浆水平正常化的患者相比，复发率显著较高。

结论/意义：因此，目前的结果表明，血浆 miR-92a 值不仅可作为诊断标志物，而且可作为监测化疗后淋巴瘤患者的新型生物标志物。